Runzi Li

Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study

Jing Liu, Jianda Hu, Y. Li, 2021, Journal of thrombosis and haemostasis : JTH.

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Jing Liu, Jie Jin, Jianda Hu, 2021, Journal of Hematology & Oncology.

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Ning Zhang, W. Dang, Zhihong Wang, 2022, Therapeutic Advances in Musculoskeletal Disease.